WO2020065080A3 - Long non-coding rna h19 for use in treatment of ischemic acute kidney injury - Google Patents

Long non-coding rna h19 for use in treatment of ischemic acute kidney injury Download PDF

Info

Publication number
WO2020065080A3
WO2020065080A3 PCT/EP2019/076331 EP2019076331W WO2020065080A3 WO 2020065080 A3 WO2020065080 A3 WO 2020065080A3 EP 2019076331 W EP2019076331 W EP 2019076331W WO 2020065080 A3 WO2020065080 A3 WO 2020065080A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
long non
coding rna
kidney injury
acute kidney
Prior art date
Application number
PCT/EP2019/076331
Other languages
French (fr)
Other versions
WO2020065080A2 (en
Inventor
Johan Lorenzen
Original Assignee
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich filed Critical Universität Zürich
Publication of WO2020065080A2 publication Critical patent/WO2020065080A2/en
Publication of WO2020065080A3 publication Critical patent/WO2020065080A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a polynucleotide agent for use in treatment or prevention of a disease or symptom associated with an ischemic state or inflammation in the kidney, wherein said polynucleotide agent comprises, or is capable of expressing, a long non-coding H19 RNA sequence.
PCT/EP2019/076331 2018-09-28 2019-09-27 Long non-coding rna h19 for use in treatment of ischemic acute kidney injury WO2020065080A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18197675 2018-09-28
EP18197675.4 2018-09-28

Publications (2)

Publication Number Publication Date
WO2020065080A2 WO2020065080A2 (en) 2020-04-02
WO2020065080A3 true WO2020065080A3 (en) 2020-05-07

Family

ID=63787732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/076331 WO2020065080A2 (en) 2018-09-28 2019-09-27 Long non-coding rna h19 for use in treatment of ischemic acute kidney injury

Country Status (1)

Country Link
WO (1) WO2020065080A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112494651A (en) * 2020-09-30 2021-03-16 吉林大学 Application of lncRNA H19 as molecular target in atherosclerosis treatment
CN114159457B (en) * 2021-12-03 2023-08-22 温州医科大学 Long-chain non-coding RNA, binding protein and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (en) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
CN104548137A (en) * 2015-01-27 2015-04-29 青岛大学 Medicinal composition containing IncRNA inhibitor and application thereof
CN105969897A (en) * 2016-07-21 2016-09-28 中国人民解放军第四军医大学 Chronic kidney disease renal function diagnostic kit based on lncRNA-H19 and application of lncRNA-H19
CN107217105A (en) * 2017-07-27 2017-09-29 江苏省原子医学研究所 A kind of cancer Combining diagnosis label and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (en) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions and methods for evaluating and treating heart failure
CN104548137A (en) * 2015-01-27 2015-04-29 青岛大学 Medicinal composition containing IncRNA inhibitor and application thereof
CN105969897A (en) * 2016-07-21 2016-09-28 中国人民解放军第四军医大学 Chronic kidney disease renal function diagnostic kit based on lncRNA-H19 and application of lncRNA-H19
CN107217105A (en) * 2017-07-27 2017-09-29 江苏省原子医学研究所 A kind of cancer Combining diagnosis label and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HANI CHOUDHRY ET AL: "Hypoxic regulation of the noncoding genome and NEAT1", BRIEFINGS IN FUNCTIONAL GENOMICS, vol. 15, no. 3, 20 November 2015 (2015-11-20), Oxford, UK, pages 174 - 185, XP055659867, ISSN: 2041-2649, DOI: 10.1093/bfgp/elv050 *
JINGYING HOU ET AL: "Long noncoding RNA H19 upregulates vascular endothelial growth factor A to enhance mesenchymal stem cells survival and angiogenic capacity by inhibiting miR-199a-5p", STEM CELL RESEARCH & THERAPY, vol. 9, no. 1, 19 April 2018 (2018-04-19), London, UK, XP055660290, ISSN: 1757-6512, DOI: 10.1186/s13287-018-0861-x *
KIR DEVIKA ET AL: "Regulation of angiogenesis by microRNAs in cardiovascular diseases", ANGIOGENESIS, KLUWER, DORDRECHT, NL, vol. 21, no. 4, 28 June 2018 (2018-06-28), pages 699 - 710, XP036622302, ISSN: 0969-6970, [retrieved on 20180628], DOI: 10.1007/S10456-018-9632-7 *
THERMO FISHER SCIENTIFIC: "hsa-miR-30a-5p", 7 May 2006 (2006-05-07), XP002797063, Retrieved from the Internet <URL:https://www.thermofisher.com/order/genome-database/browse/mimics-inhibitors/keyword/hsa-mir-30a-5p?SID=srch-uc-mimic-hsa-mir-30a-5p&mode=and#filters=> [retrieved on 20200117] *

Also Published As

Publication number Publication date
WO2020065080A2 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
JP2019512824A5 (en)
WO2019032662A8 (en) Clec9a binding agents and use thereof
WO2020065080A3 (en) Long non-coding rna h19 for use in treatment of ischemic acute kidney injury
JP2015133993A5 (en)
EP3355879A4 (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
AU2018295907A1 (en) Internal organ, injury and pain treatment
WO2015138532A3 (en) Methods for the treatment of kidney fibrosis
WO2017008033A8 (en) Pyrrolidine carboxamido derivatives and methods for preparing and using the same
WO2019048930A3 (en) Bacteriophage for modulating inflammatory bowel disease
CL2014001556A1 (en) Method to identify specific inhibitory compounds of connexin hemichannels and use of said inhibitors to treat and / or prevent inflammatory diseases, vascular disorders, arrhythmia, chronic wounds, retinal neuroprotection, fibrosis and pain.
WO2016050835A3 (en) Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
SG11202108333YA (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria
WO2015164057A3 (en) System for continuous stent advancement
WO2017035319A8 (en) Methods for treatment of polycystic kidney disease
EP3187370A3 (en) Steering wheel turn signal
WO2016102930A3 (en) Medical device for treating a vein
WO2019203753A3 (en) The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
WO2016009225A3 (en) Method for preventing or treating a protein aggregation disease
WO2015165980A3 (en) Treatment and prevention of alzheimer&#39;s disease (ad)
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2015157476A3 (en) Pdia4 protein as a target for diagnosis, monitoring and treatment of diabetes
EP3646899A4 (en) Lysosomal storage disease treatment agent
WO2015200349A3 (en) Elastase inhibitors
曹青青 The Application of TBLT Questioning Strategies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19778998

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19778998

Country of ref document: EP

Kind code of ref document: A2